Friday
Oct092015

NCT02579252

24 Months Safety and Efficacy Study of AADvac1 in Patients with Mild Alzheimer's Disease (ADAMANT)

A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Sponsor: Axon Neuroscience SE
Phase 2 

PrintView Printer Friendly Version

EmailEmail Article to Friend